Key clinical point : Bosutinib is effective in patients with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) resistant/intolerant to prior therapy across age groups and the Charlson Comorbidity Index score without the age component (mCCI) scores.
Major finding : A substantial proportion of patients attained or maintained molecular response across age groups and mCCI scores molecular response. Older patients and those with mCCI ≥4 showed a trend towards higher rates of grade 3/4 treatment-related adverse events.
Study details : The data come from the ongoing, phase 4, single-arm, open-label BYOND study examining the safety and efficacy of bosutinib.
Disclosures: The study was sponsored by Pfizer. No data available regarding conflicts of interest.
Source: Gambacorti-Passerini C et al. Poster. Abstract 055 . BSH 2020. 2020 Nov 9-14.